Rituximab biosimilar (Shenghe (China) Biopharm)

利妥昔单抗生物类似药（盛禾（中国）生物制药）

Report date: 2025/06/06 16:28:34

Base Information

Drug NameRituximab biosimilar (Shenghe (China) Biopharm)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaNDA/BLA

Originator CompaniesSunHo (China) BioPharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSunHo (China) BioPharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A